肾康注射液联合羟苯磺酸钙治疗慢性肾脏病的临床观察

目的观察肾康注射液联合羟苯磺酸钙治疗慢性肾脏病(CKD)3~4期的临床疗效。方法将92例CKD 3~4期患者随机分为3组:对照组(A组)30例、羟苯磺酸钙组(B组)31例和肾康注射液组(C组)31例,疗程均为1个月。观察治疗前后24 h尿蛋白定量(24 h UTP)、血肌酐(Scr)、尿素氮(BUN)、尿酸(UA)、血清胱抑素C(CysC)等指标变化情况。结果 B组治疗后24 h UTP、CysC水平较A组明显下降,C组治疗后24 h UTP水平较A组明显下降;C组治疗后BUN、UA及CysC水平均显著低于B组。结论肾康注射液联合羟苯磺酸钙能有效降低CKD患者BUN、UA及CysC水平,延缓肾功能减退,具有良好的肾保护作用。

Clinical observation of Shenkang injection combined with calcium dobesilate for chronic kidney disease

Objective To observe the clinical effect of Shenkang injection combined with calcium dobesilate in the treatment of chronic kidney disease(CKD) at the 3rd to 4th phase.Methods Ninety-two CKD patients at the 3rd to 4th phase were randomly divided into 3 groups: 30 cases in control group(group A),31 cases in calcium dobesilate group(group B) and 31 cases in Shenkang injection group(group C).The courses of treatment in 3 groups were all 1 month.The changes of 24 h urine protein quantitation 24 h(24 h UTP),serum creatinine(Scr),urea nitrogen(BUN),uric acid(UA) and cystatin C(CysC) before and after treatment were observed.Results Compared with group A,the levels of 24 h UTP and CysC after treatment in group B both decreased significantly,and the level of 24 h UTP after treatment in group C reduced markedly.The differences in groups A and B showed statistical significance.After treatment,the levels of BUN,UA and CysC in group C were all lower than those in group B notably.Conclusion Shenkang injection combined with calcium dobesilate can effectively decrease the levels of BUN,UA and CysC of CKD patients and delay the declination of renal function,which has a better effect of renal function.